Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Renaissance of Radiotherapy in Intestinal Lymphoma? 10-Year Efficacy and Tolerance in Multimodal Treatment of 134 Patients: Follow-up of Two German Multicenter Consecutive Prospective Phase II Trials.
Reinartz G, Molavi Tabrizi C, Liersch R, Ullerich H, Hering D, Willborn K, Schultze J, Micke O, Ruebe C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Moeller P, Neubauer A, Wilhelm M, Lenz G, Berdel WE, Willich N, Eich HT. Reinartz G, et al. Among authors: pott c. Oncologist. 2020 May;25(5):e816-e832. doi: 10.1634/theoncologist.2019-0783. Epub 2020 Mar 27. Oncologist. 2020. PMID: 32219909 Free PMC article. Clinical Trial.
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Brüggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M. Pott C, et al. Blood. 2006 Mar 15;107(6):2271-8. doi: 10.1182/blood-2005-07-2845. Epub 2005 Dec 6. Blood. 2006. PMID: 16332971 Free article.
(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.
Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A. Scholz CW, et al. Among authors: pott c. J Clin Oncol. 2013 Jan 20;31(3):308-13. doi: 10.1200/JCO.2011.41.1553. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233718 Clinical Trial.
Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).
Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT. Reinartz G, et al. Among authors: pott c. Strahlenther Onkol. 2019 Jun;195(6):544-557. doi: 10.1007/s00066-019-01446-5. Epub 2019 Mar 11. Strahlenther Onkol. 2019. PMID: 30859254 English.
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L, Dreyling M, Dürig J, Engelhard M, Hohloch K, Viardot A, Witzens-Harig M, Kieser M, Klapper W, Pott C, Herfarth K. König L, et al. Among authors: pott c. Trials. 2019 Aug 30;20(1):544. doi: 10.1186/s13063-019-3614-y. Trials. 2019. PMID: 31470902 Free PMC article.
Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study.
Herfarth K, Borchmann P, Schnaidt S, Hohloch K, Budach V, Engelhard M, Viardot A, Engenhart-Cabillic R, Keller U, Reinartz G, Eich HT, Witzens-Harig M, Hess CF, Dörken B, Dürig J, Wiegel T, Hiddemann W, Hoster E, Pott C, Dreyling M. Herfarth K, et al. Among authors: pott c. Hemasphere. 2018 Nov 30;2(6):e160. doi: 10.1097/HS9.0000000000000160. eCollection 2018 Dec. Hemasphere. 2018. PMID: 31723798 Free PMC article.
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S. Liebers N, et al. Among authors: pott c. Blood Adv. 2021 Jul 13;5(13):2707-2716. doi: 10.1182/bloodadvances.2020004155. Blood Adv. 2021. PMID: 34196677 Free PMC article.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Hess G, Hüttmann A, Witzens-Harig M, Dreyling MH, Keller U, Marks R, Ernst T, Pott C, Viardot A, Frontzek F, Trautmann M, Ruckes C, Deuster O, Rosenwald A, Theobald M, Lenz G. Hess G, et al. Among authors: pott c. Br J Haematol. 2022 Aug;198(3):482-491. doi: 10.1111/bjh.18161. Epub 2022 Apr 1. Br J Haematol. 2022. PMID: 35362552 Clinical Trial.
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial.
Zimmermann H, Koenecke C, Dreyling MH, Pott C, Dührsen U, Hahn D, Meidenbauer N, Hauser IA, Rummel MJ, Wolf D, Heuser M, Schmidt C, Schlattmann P, Ritgen M, Siebert R, Oschlies I, Anagnostopoulos I, Trappe RU. Zimmermann H, et al. Among authors: pott c. Leukemia. 2022 Oct;36(10):2468-2478. doi: 10.1038/s41375-022-01667-1. Epub 2022 Aug 16. Leukemia. 2022. PMID: 35974101 Free PMC article. Clinical Trial.
246 results